Overall , breast cancer mortality was much the same between groups ( @ % -LSB- @-@ -RSB- for TARGIT vs @ % -LSB- @-@ -RSB- for EBRT ; p = @ ) but there were significantly fewer non-breast-cancer deaths with TARGIT ( @ % -LSB- @-@ -RSB- vs @ % -LSB- @-@ -RSB- ; p = @ ) , attributable to fewer deaths from cardiovascular causes and other cancers .